Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902174 · ClinicalTrials.gov registry record · Phase 3
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT00902174 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 202 participants.
The verdict
NCT00902174, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
Interventions
- DRUG Placebo
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00902174
The ClinicalTrials.gov registry entry for NCT00902174 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00902174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00902174 about?
NCT00902174 is a clinical study titled "Imatinib (QTI571) in Pulmonary Arterial Hypertension". A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
What is the current status of trial NCT00902174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2009-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00902174?
The interventions under investigation include: Placebo (DRUG), imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00902174?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.